News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia

December 7, 2020 • 7:00 AM EST

Vaccine Genome Researchers Report 99.7% Colinear Identity Between a U.S. Civil War Era Smallpox Vaccine and Horsepox Virus

December 4, 2020 • 8:00 AM EST

Tonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human Primates

November 16, 2020 • 7:00 AM EST

Tonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development Summit

November 12, 2020 • 4:31 PM EST

Tonix Pharmaceuticals to Participate in Upcoming November Conferences

November 11, 2020 • 7:00 AM EST

Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit

November 9, 2020 • 4:15 PM EST

Tonix Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights

November 9, 2020 • 8:30 AM EST

Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

October 15, 2020 • 7:00 AM EDT

Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital

October 7, 2020 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Plan to Complete the Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia with Currently Enrolled Participants Based on Results of Interim Analysis

September 29, 2020 • 4:05 PM EDT

« Previous
1...
2
3
4
5
6
7
8
9
10
11
...43
Next »

Show All